Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells

Alex Y. Chang(Cornell University), Miao Wang(Zhejiang Chinese Medical University)

BMC Cancer

May 30, 2013

10.1186/1471-2407-13-267

Cited by 75

Related Papers

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

|The Lancet|2005|2.1k

Genomic variation in 3,010 diverse accessions of Asian cultivated rice

|Nature|2018|1.9k

Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

|Journal of Clinical Oncology|2006|702

A Role for Peroxisome Proliferator-activated Receptor γ Coactivator 1 (PGC-1) in the Regulation of Cardiac Mitochondrial Phospholipid Biosynthesis

|Journal of Biological Chemistry|2013|87

The cyclooxygenase-1/mPGES-1/endothelial prostaglandin EP4 receptor pathway constrains myocardial ischemia-reperfusion injury

|Nature Communications|2019|76